Signal Peptide Database - Mammalia

 Entry Details
ID   430
Source Database   UniProtKB/Swiss-Prot
UniProtKB/Swiss-Prot Accession Number   P16382    (Created: 1990-08-01 Updated: 2008-12-16)
UniProtKB/Swiss-Prot Entry Name   IL4RA_MOUSE
Protein Name   Interleukin-4 receptor alpha chain
Gene   Il4r
Organism Scientific   Mus musculus
Organism Common   Mouse
Lineage   Eukaryota
  Metazoa
    Chordata
      Craniata
        Vertebrata
          Euteleostomi
            Mammalia
              Eutheria
                Euarchontoglires
                  Glires
                    Rodentia
                      Sciurognathi
                        Muroidea
                          Muridae
                            Murinae
                              Mus
Protein Length [aa]   810
Protein Mass [Da]   87627
Features  
TypeDescriptionStatusStartEnd
signal peptide         1   25
chain   Interleukin-4 receptor alpha chain      26   810
chain   Soluble interleukin-4 receptor alpha chain      26   0
disulfide bond      by similarity   34   44
disulfide bond      by similarity   75   87
transmembrane region      potential   234   257
topological domain   Extracellular   potential   26   233
topological domain   Cytoplasmic   potential   258   810
domain   Fibronectin type-III      124   220
region of interest   Required for IRS1 activation and IL4- induced cell growth   by similarity   441   557
region of interest   Required for IL4-induced gene expression   by similarity   557   653
modified residue   Phosphotyrosine      500   500
modified residue   Phosphotyrosine   probable   575   575
modified residue   Phosphotyrosine   probable   603   603
modified residue   Phosphotyrosine   probable   631   631
glycosylation site   N-linked (GlcNAc...)   potential   72   72
glycosylation site   N-linked (GlcNAc...)   potential   129   129
glycosylation site   N-linked (GlcNAc...)   potential   135   135
glycosylation site   N-linked (GlcNAc...)      163   163
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J; reduced IL4-neutralizing capacity of soluble form)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
sequence variant   (in strain: BALB/c, AKR/J, SJL/ J)      0   0
splice variant   (in isoform 2)      0   0
splice variant   (in isoform 2)      231   810
splice variant   (in isoform 3)      258   810
compositionally biased region   Poly-Glu      376   381
compositionally biased region   Poly-Glu      527   530
short sequence motif   WSXWS motif      213   217
short sequence motif   Box 1 motif      263   271
short sequence motif   ITIM motif      707   712
SP Length   25
 ----+----1----+----2----+----3----+----4----+----5
Signal Peptide MGRLCTKFLTSVGCLILLLVTGSGS
Sequence MGRLCTKFLTSVGCLILLLVTGSGSIKVLGEPTCFSDYIRTSTCEWFLDS
AVDCSSQLCLHYRLMFFEFSE
NLTCIPRNSASTVCVCHMEMNRPVQSDRY
QMELWAEHRQLWQGSFSPSGNVK
PLAPDNLTLHTNVSDEWLLTWNNLYPS
NNLLYKDLISMV
NISREDNPAEFIVYNVTYKEPRLSFPINILMSGVYYTA
RVRVRSQILTGT
WSEWSPSITWYNHFQLPLIQRLPLGVTISCLCIPLFCL
FCYFSIT
KIKKIWWDQIPTPARSPLVAIIIQDAQVPLWDKQTRSQESTKY
PHWKTCLDKLLPCLLKHRVKKKTDFPKAAPTKSLQSPGKAGWCPMEVSRT
VLWPENVSVSVVRCMELFEAPVQNV
EEEEDEIVKEDLSMSPENSGGCGFQ
ESQADIMARLTENLFSDLLEAENGGLGQSALAESCSPLPSGSGQASVSWA
CLPMGPSEEATCQVTEQPSHPGPLSGSPAQSAPTLACTQVPLVLADNPAY
RSFSDCCSPAPNPGELAPEQQQADHL
EEEEPPSPADPHSSGPPMQPVESW
EQILHMSVLQHGAAAGSTPAPAGGYQEFVQAVKQGAAQDPGVPGVRPSGD
PGYKAFSSLLSSNGIRGDTAAAGTDDGHGGYKPFQNPVPNQSPSSVPLFT
FGLDTELSPSPLNSDPPKSPPECLGLELGLKGGDWVKAPPPADQVPKPFG
DDLGFG
IVYSSLTCHLCGHLKQHHSQEEGGQSPIVASPGCGCCYDDRSPS
LGSLSGALESCPEGIPPEANLMSAPKTPSNLSGEGKGPGHSPVPSQTTEV
PVGALGIAVS
Original MGRLCTKFLTSVGCLILLLVTGSGSIKVLGEPTCFSDYIRTSTCEWFLDS
AVDCSSQLCLHYRLMFFEFSENLTCIPRNSASTVCVCHMEMNRPVQSDRY
QMELWAEHRQLWQGSFSPSGNVKPLAPDNLTLHTNVSDEWLLTWNNLYPS
NNLLYKDLISMVNISREDNPAEFIVYNVTYKEPRLSFPINILMSGVYYTA
RVRVRSQILTGTWSEWSPSITWYNHFQLPLIQRLPLGVTISCLCIPLFCL
FCYFSITKIKKIWWDQIPTPARSPLVAIIIQDAQVPLWDKQTRSQESTKY
PHWKTCLDKLLPCLLKHRVKKKTDFPKAAPTKSLQSPGKAGWCPMEVSRT
VLWPENVSVSVVRCMELFEAPVQNVEEEEDEIVKEDLSMSPENSGGCGFQ
ESQADIMARLTENLFSDLLEAENGGLGQSALAESCSPLPSGSGQASVSWA
CLPMGPSEEATCQVTEQPSHPGPLSGSPAQSAPTLACTQVPLVLADNPAY
RSFSDCCSPAPNPGELAPEQQQADHLEEEEPPSPADPHSSGPPMQPVESW
EQILHMSVLQHGAAAGSTPAPAGGYQEFVQAVKQGAAQDPGVPGVRPSGD
PGYKAFSSLLSSNGIRGDTAAAGTDDGHGGYKPFQNPVPNQSPSSVPLFT
FGLDTELSPSPLNSDPPKSPPECLGLELGLKGGDWVKAPPPADQVPKPFG
DDLGFGIVYSSLTCHLCGHLKQHHSQEEGGQSPIVASPGCGCCYDDRSPS
LGSLSGALESCPEGIPPEANLMSAPKTPSNLSGEGKGPGHSPVPSQTTEV
PVGALGIAVS
 ----+----1----+----2----+----3----+----4----+----5
Hydropathies  
 

© 2007-2017 Dr. Katja Kapp, Kassel & thpr.net e. K., Dresden, Germany, last update 2010-06-11